
## MariÃ;n MokÃ;Å^

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7024721/publications.pdf Version: 2024-02-01



ΜΑΡΙΑ:Ν ΜΟΚΑ:Δ^

#	Article	IF	CITATIONS
1	Endothelial and platelet markers in diabetes mellitus type 2. World Journal of Diabetes, 2015, 6, 423.	3.5	35
2	Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Research and Clinical Practice, 2008, 81, 238-242.	2.8	34
3	The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e308-e313.	0.9	30
4	Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1199-1207.	1.7	28
5	Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 2017, 18, 609-621.	1.2	23
6	Waist Circumference as an Independent Risk Factor for NODAT. Annals of Transplantation, 2015, 20, 154-159.	0.9	15
7	Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. Seminars in Thrombosis and Hemostasis, 2019, 45, 846-850.	2.7	14
8	Outcomes of Patients with Newly Diagnosed Cardiac Myxoma: A Retrospective Multicentric Study. BioMed Research International, 2018, 2018, 1-5.	1.9	12
9	Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. Journal of Cardiovascular Pharmacology, 2021, 78, e122-e127.	1.9	12
10	Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. American Journal of Emergency Medicine, 2014, 32, 461-465.	1.6	11
11	First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 914-919.	1.7	11
12	Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. European Journal of Clinical Pharmacology, 2022, 78, 557-564.	1.9	11
13	First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. Journal of Thrombosis and Thrombolysis, 2018, 46, 393-398.	2.1	10
14	Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. Drugs and Aging, 2018, 35, 539-544.	2.7	10
15	Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study. Journal of Thrombosis and Thrombolysis, 2019, 47, 140-145.	2.1	10
16	Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?. Diabetes Research and Clinical Practice, 2018, 135, 172-177.	2.8	9
17	Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs. Journal of Cardiovascular Pharmacology, 2018, 72, 71-76.	1.9	9
18	The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2020, 75, 333-335.	1.9	9

MariÃin MokÃiÅ^

#	Article	IF	CITATIONS
19	ROTEM Testing for Direct Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2021, 47, 815-823.	2.7	9
20	Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of Diabetes Research, 2016, 2016, 1-7.	2.3	8
21	Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?. Pediatric Cardiology, 2019, 40, 1431-1438.	1.3	8
22	Impact of Dabigatran Treatment on Rotation Thromboelastometry. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962098390.	1.7	8
23	Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation. Journal of Diabetes Research, 2019, 2019, 1-12.	2.3	7
24	Effect of Bisoprolol on the Level of Dabigatran. American Journal of Therapeutics, 2020, 27, e159-e164.	0.9	7
25	Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. European Journal of Clinical Pharmacology, 2019, 75, 875-877.	1.9	6
26	Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases. Diagnostics, 2021, 11, 143.	2.6	6
27	How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?. European Journal of Clinical Pharmacology, 2019, 75, 285-286.	1.9	5
28	Does atorvastatin therapy change the antiâ€Xa activity in xabansâ€ŧreated patients with atrial fibrillation?. Pharmacology Research and Perspectives, 2021, 9, e00730.	2.4	5
29	The role of vaspin as a predictor of coronary angiography result in SCAD (stable coronary artery) Tj ETQq1 1 0.7	84314 rgB 1.7	T /Qverlock 1
30	Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?. Journal of Thrombosis and Thrombolysis, 2019, 48, 619-622.	2.1	4
31	Edoxaban affects TRAP-dependent platelet aggregation. Journal of Thrombosis and Thrombolysis, 2020, 49, 578-583.	2.1	4
32	Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal. Current Drug Metabolism, 2017, 18, 643-650.	1.2	4
33	Therapeutic plasma exchange in secondary prevention of acute pancreatitis in pregnant patient with familial hyperchylomicronemia. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 90-94.	0.6	4
34	Endogenous Digoxin-like Immunoactivity in Subjects With Diabetes Mellitus and Hypertension. American Journal of Hypertension, 1998, 11, 667-676.	2.0	3
35	Insulin Pump Therapy – Influence on Body Fat Redistribution, Skeletal Muscle Mass and Ghrelin, Leptin Changes in T1D Patients. Obesity Facts, 2018, 11, 454-464.	3.4	3
36	Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy. Scandinavian Cardiovascular Journal, 2018, 52, 227-231.	1.2	3

MariÃin MokÃiÅ^

#	Article	IF	CITATIONS
37	Severe hypoglycemia due to insulin self-injection as a cause of acute ST elevation myocardial infarction. Journal of Diabetes and Metabolic Disorders, 2019, 18, 739-742.	1.9	3
38	Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation. American Journal of Therapeutics, 2020, 27, e507-e509.	0.9	3
39	The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Journal of Diabetes Research, 2016, 2016, 1-6.	2.3	2
40	Assessing the hemostasis with thromboelastometry in direct oral anticoagulants-treated patients with atrial fibrillation. Thrombosis Research, 2020, 191, 38-41.	1.7	2
41	Insulinoma presenting with postprandial hypoglycemia and a low body mass index: A case report. World Journal of Clinical Cases, 2020, 8, 4169-4176.	0.8	2
42	Anti-Xa Activity-Guided Edoxaban Therapy for Cancer-Associated Venous Thromboembolism?. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	1
43	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	2.3	1
44	Sweet's syndrome in a patient with squamous cell carcinoma in terminal of an agnogenic myeloid bone marrow metaplasia. Journal of the European Academy of Dermatology and Venereology, 1997, 8, 55-58.	2.4	0
45	Apixaban. American Journal of Therapeutics, 2021, Publish Ahead of Print, e212-e218.	0.9	0
46	Recurrent Ileal Variceal Bleeding as a Diagnostic and Therapeutic Challenge. Case Reports in Gastrointestinal Medicine, 2022, 2022, 1-4.	0.3	0